[ @entity787 ( @entity787 ) in XXXX . Clinical value].

@entity1 @entity0 @entity5 @entity787 @entity3
The investigation of clinical markers, i.e. substances produced and released by @entity5 , has been encouraged by the need for early diagnosis to increase the chances of successful treatment, and for biological parameters indicative of the progress of the disease itself. A study designed to appraise the usefulness of @entity5 -associated antigens in this respect in cases of @entity0 has been in operation for about 3 years at Oncological Service of the 2nd Obstetric and Gynaecological Clinic, University of Rome. @entity787 ( @entity787 ) values in 71 @entity1 in the initial stages and with @entity3 followed for 24 months are presented. @entity787 levels are related to @entity5 stage, progression, and prognosis. High values appear to be associated with diffusion of the disease: 48% in initial cases; 69% in advanced cases. @entity787 is specific for this type of @entity5 . Even so, high values give an effective expression of its progress by identifying @entity1 with a greated likelihood of recurrence. It is particularly useful as an early indication of recurrence itself. In addition, it is of assistance in monitoring the progress of treatment.
